Jefferies Raises Revenue, EPS Estimates for Agilent | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Jefferies today raised its EPS estimate for Agilent Technologies to $2.63 from $2.60, on the strength of recent organic order trends and anticipated minimal effects from the Japanese earthquake and tsunami.

The investment firm also increased the share-price target to $56 from $55 and revenue estimates for full-year 2011 to $6.39 billion from $6.35 billion. It has a "Buy" rating on Agilent.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.

A cancer researcher retracts 19 articles from one journal for image manipulation, according to Retraction Watch.

Precision medicine has to consider context in addition to genetic mutations in cancer treatment, Medscape reports.

Genomics may help the Cavendish banana from succumbing to fungal infections, a trio of researchers writes at the Conversation.